CClinicalTrials.gg
CompletedNCT07264387RTWS2Updated Sep 9, 2026

Predictive Factors for Return to Work After a First Stroke Treated at Clermont-Ferrand University Hospital in Puy de Dôme Between January 2020 and December 2024

An observational study in Stroke, sponsored by University Hospital, Clermont-Ferrand. Completed at 2 sites in France. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by University Hospital, Clermont-Ferrand · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
190
Ages
18 Years to 64 Years
Sex
All
01

Study summary

Stroke is a leading cause of acquired motor disability and the second most common cause of major cognitive impairment worldwide. In France, approximately 150,000 new cases occur annually, with around 31% affecting individuals of working age, making return to work (RTW) a critical public health issue. Beyond the medical burden, stroke has profound socio-economic consequences, including loss of productivity, prolonged sick leave, part-time resumption, and the need for workplace adaptations. While RTW after stroke has been investigated, major gaps remain. No standardized recommendations exist for vocational reintegration, and predictive factors are still debated. Quantitative determinants such as stroke type, severity, functional independence, and occupational characteristics have been identified, but qualitative aspects-including self-efficacy, perceived social burden, employer relationships, and motivation-are poorly documented. Moreover, cognitive deficits are often insufficiently characterized, as screening tools such as MMSE or MoCA lack the sensitivity of comprehensive neuropsychological assessments. The impact of revascularization procedures on RTW and the ability to sustain employment after initial resumption also remain unclear. Importantly, no recent data are available in the Auvergne region, despite evolving labor policies that may influence reintegration trajectories. This observational study therefore aims to identify both quantitative and qualitative predictors of RTW after ischemic or hemorrhagic stroke, describe vocational pathways in a regional cohort, and explore barriers and facilitators to long-term reintegration. Ultimately, the study seeks to provide updated evidence to guide tailored rehabilitation and socio-professional reintegration strategies, supporting sustainable RTW in working-age stroke survivors.

02

Conditions studied

  • Stroke

Browse trials for

Keywords

  • stroke
  • return to work
  • predictive factors
03

In context

Stroke

7,283 studies on the registry are indexed under Stroke; 2,013 are open to participants now.

This study's enrollment of 190 is above the median of 160 across 1,692 observational studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

University Hospital, Clermont-Ferrand is the lead sponsor of 841 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Stroke management follows a continuum, starting with acute care in neurology and neurosurgery, then progressing to medium- and long-term multidisciplinary rehabilitation in the Physical Medicine and Rehabilitation (PMR) department of Clermont-Ferrand University Hospital. Within this context, return to work is a key objective, supported by the expertise of PMR teams and close collaboration with neurology and neurosurgery. To conduct this study, authorisation to access medical records was granted by the Medical Information Department (DIM), covering patients under 64 years old admitted for ischaemic or haemorrhagic stroke between January 2020 and December 2024. Screening will be performed on hospitalisations in neurology and neurosurgery, and all eligible patients experiencing a first stroke during this period will be invited to participate.

Inclusion criteria

  • Patients who have suffered an ischaemic stroke according to ICD-10 (ICD-10 code: I63 (cerebral infarction) I64 (unspecified stroke), I69 (sequelae of cerebrovascular disease) or patients who have had a haemorrhagic stroke according to ICD-10 (ICD-10 code: I60, I61 and I62) between January 2020 and March 2024
  • Patients of working age/under 64 years of age (legal retirement age)
  • Patients with an employment contract at the time of the stroke
  • Patients treated at Clermont-Ferrand University Hospital
  • Post-stroke consultation recorded in the patient's medical file
  • Patients affiliated with the social security system
  • Patients who have not objected to participating in the study

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of ischaemic or haemorrhagic stroke
  • Patients with a history of head trauma with neurological sequelae corresponding to codes S060, S061, S062, S063, S065, S066, S067, S068 and S069
  • Patients who died as a result of stroke
  • Patients unable to respond to telephone questionnaires
  • Patients under guardianship or trusteeship
  • Patients who have suffered a transient ischaemic attack (TIA) (G459 according to ICD 10)
  • Patients who were in early retirement at the time of assessment
  • No information on employment after stroke in the medical file
  • Patients with category 2 or 3 disability prior to stroke due to another condition
  • Patients on sick leave prior to stroke due to another condition
  • Patients receiving RSA income support
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
190 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Return to work rate

    Percentage of return to work after a first ischaemic or haemorrhagic stroke between January 2020 and December 2024 in patients of working age.

    Time frame: At inclusion

  2. Factors correlated with return to work

    Determine the factors associated with return to work (gender)

    Time frame: At inclusion

  3. Factors correlated with return to work

    Determine the factors associated with return to work (stroke severity)

    Time frame: At inclusion

  4. Factors correlated with return to work

    Determine the factors associated with return to work (stroke type (ischaemic or haemorrhagic)).

    Time frame: At inclusion

  5. Factors correlated with return to work

    Determine the factors associated with return to work (independence)

    Time frame: At inclusion

  6. Factors correlated with return to work

    Determine the factors associated with return to work (occupation)

    Time frame: At inclusion

Secondary outcomes

  1. Quality of life after stroke

    The Short-Form-12 (SF-12) questionnaire is a standardized self-administered questionnaire used to assess health-related quality of life. It comprises 12 questions covering 8 domains: physical activities, physical and mental limitations, pain, perceived general health, vitality, mental health and social relationships. Each item is rated on a 5- or 6-point Likert scale. The responses are used to calculate two scores: a physical composite score (PCS) and a mental composite score (MCS), each ranging from 0 (perceived health status very poor) to 100 (perceived health status optimal).

    Time frame: At inclusion

  2. Anxiety and Depression scale

    The Hospital Anxiety and Depression Scale (HADs) questionnaire is a psychometric self-assessment questionnaire consisting of 14 items divided into two subscales (anxiety and depression) of seven items each. Each item is rated on a scale of 0 to 3. A score is given for each subscale, A for anxiety and D for depression. The score can range from 0 (no anxiety and/or depressive disorders) to 21 (proven anxiety and/or depressive disorders of varying severity) for each subscale.

    Time frame: At inclusion

  3. Fatigue Severity Scale

    The Fatigue Severity Scale (FSS) questionnaire is a self-assessment tool used to evaluate the severity of fatigue and its impact on daily activities. This questionnaire consists of nine items rated on a seven-point Likert scale, ranging from 1 ('strongly disagree') to 7 ('strongly agree'). The score ranges from 7 (no fatigue in daily activities) to 63 (extreme fatigue in daily activities). A score above 36 indicates that the patient may need to have their fatigue assessed by a healthcare professional.

    Time frame: At inclusion

  4. Predictive score for return-to-work rate

    Develop a predictive score for return to work using the predictive factors for return to work identified in the main objective.

    Time frame: At inclusion

  5. Job retention

    To study job retention and its association with factors such as stroke severity.

    Time frame: At inclusion

07

Study locations

2 sites
  • Clermont Ferrand University Hospital, Louise Michel site
    Cébazat, France 63118, France
  • CHU Clermont-Ferrand, Louise Michel
    Clermont-Ferrand, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07264387
Lead sponsor
University Hospital, Clermont-Ferrand
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Oct 29, 2025
Primary completion
Jan 22, 2026
Completion
Jan 22, 2026
Last update
Sep 9, 2026

Study contacts

Lise Laclautre
study director · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion